Compare Johnson & Johnson (JNJ) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs McCormick & Company, Incorporated — how do they compare? Johnson & Johnson trades at $261.25 (market cap $626.09B), while McCormick & Company, Incorporated trades at $53.21 (market cap $14.22B). The key difference: Johnson & Johnson is far larger — about 44× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| JNJ | MKC | |
|---|---|---|
Market Cap | $626.09B | $14.22B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $72.26 |
52-Week Low | $172.78 | $45.60 |
Enterprise Value | $654.37B | $18.82B |
Dividend Yield | 2.06% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
MKC trades at $53.13, up 0.32% today, with a bullish technical signal and strong profitability metrics including a 21.91% net income margin and 25.7% ROE. Recent Q2 2026 results beat expectations, driven by acquisitions and margin expansion. The pending Unilever Foods merger, expected to close in 2027, dominates news flow and offers transformative growth potential.
The outlook is positive, with a consensus price target of $59.67 implying 12% upside. Key opportunities include merger synergies and sustained dividend growth, while risks involve integration execution and soft consumer volumes. Analysts are mixed but lean bullish on valuation and strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
